Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference

Behavioural Brain Research

Volumn 191, Issue 1, 2008, Pages 17-25

  Bahi, Amine ^a   Kusnecov, Alexander W ^b   Dreyer, Jean Luc ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Addiction; Cocaine; Conditioned place preference; Drug reinstatement; In vivo gene transfer; Lentivirus; siRNA; Urokinase

Indexed keywords

AMPHETAMINE; B 428; COCAINE; DOXYCYCLINE; FN 439; LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE INHIBITOR; MORPHINE; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR MODIFICATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG REEXPOSURE; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LENTIVIRINAE; LIMBIC CORTEX; LOCOMOTION; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REWARD; VENTRAL TEGMENTUM;

AMIDINES; ANALYSIS OF VARIANCE; ANESTHETICS, LOCAL; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; LENTIVIRUS; MALE; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); THIOPHENES; URINARY PLASMINOGEN ACTIVATOR;

EID: 43249093860     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.03.004     Document Type: Article

References (71)

1. Masos T., and Miskin R. Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. Brain Res Mol Brain Res 35 (1996) 139-148
2. Del Bigio M.R., Hosain S., and Altumbabic M. Localization of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse forebrain during postnatal development. Int J Dev Neurosci 17 (1999) 387-399
3. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2 (2001) 119-128
4. Robinson T.E., and Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17 (1997) 8491-8497
5. Robinson T.E., and Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 11 (1999) 1598-1604
6. Robinson T.E., and Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47 Suppl 1 (2004) 33-46
7. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
8. Wise R.A. Neurobiology of addiction. Curr Opin Neurobiol 6 (1996) 243-251
9. Wise R.A. Addiction becomes a brain disease. Neuron 26 (2000) 27-33
10. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
11. Di Chiara G., and Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 7 (2007) 69-76
12. Bahi A., Boyer F., Gumy C., Kafri T., and Dreyer J.L. In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioral changes in chronic cocaine administration. Eur J Neurosci 20 (2004) 3473-3488
13. Yamada K., Nagai T., and Nabeshima T. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci 97 (2005) 157-161
14. Iwata N., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., et al. No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: a collaborative study by the Japanese Genetics Initiative for Drug Abuse. Ann N Y Acad Sci 1025 (2004) 34-38
15. Hyman S.E. Addiction: a disease of learning and memory. Am J Psychiatry 162 (2005) 1414-1422
16. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 101 (2004) 3650-3655
17. Ripley T.L., Rocha B.A., Oglesby M.W., and Stephens D.N. Increased sensitivity to cocaine, and over-responding during cocaine self-administration in tPA knockout mice. Brain Res 826 (1999) 117-127
18. Bahi A., Boyer F., Kafri T., and Dreyer J.L. Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion. J Neurochem 98 (2006) 1619-1631
19. Bahi A., and Dreyer J.L. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav 7 2 (2008) 244-256
20. Bahi A., Boyer F., Kafri T., and Dreyer J.L. CD81-induced behavioral changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur J Neurosci 19 (2004) 1621-1633
21. Bahi A., Boyer F., Bussard G., and Dreyer J.L. Silencing dopamine D3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur J Neurosci 21 (2005) 3415-3426
22. Bahi A., Boyer F., Kolira M., and Dreyer J.L. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behavior. J Neurochem 92 (2005) 1243-1255
23. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
24. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edn. (1998), Academic Press, San Diego, USA
25. Mueller D., and Stewart J. Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res 115 (2000) 39-47
26. Itzhak Y., and Martin J.L. Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. Neuropsychopharmacology 26 (2002) 130-134
27. Bohn L.M., Gainetdinov R.R., Sotnikova T.D., Medvedev I.O., Lefkowitz R.J., Dykstra L.A., et al. Enhanced rewarding properties of morphine, but not cocaine, in beta-arrestin-2 knock-out mice. J Neurosci 23 (2003) 10265-10273
28. Medvedev I.O., Gainetdinov R.R., Sotnikova T.D., Bohn L.M., Caron M.G., and Dykstra L.A. Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) 180 (2005) 408-413
29. Orsini C., Bonito-Oliva A., Conversi D., and Cabib S. Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL/6 and DBA/2 inbred strains. Psychopharmacology (Berl) 181 (2005) 327-336
30. Roma P.G., and Riley A.L. Apparatus bias and the use of light and texture in place conditioning. Pharmacol Biochem Behav 82 (2005) 163-169
31. Becker A., Schmitz M., and Grecksch G. Kindling modifies morphine, cocaine and ethanol place preference. Exp Brain Res 168 (2006) 33-40
32. Font L., Aragon C.M., and Miquel M. Ethanol-induced conditioned place preference, but not aversion, is blocked by treatment with d-penicillamine, an inactivation agent for acetaldehyde. Psychopharmacology (Berl) 184 (2006) 56-64
33. Valjent E., Corbille A.G., Bertran-Gonzalez J., Herve D., and Girault J.A. Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci USA 103 (2006) 2932-2937
34. Barot S.K., Ferguson S.M., and Neumaier J.F. 5-HT(1B) receptors in nucleus accumbens efferents enhance both rewarding and aversive effects of cocaine. Eur J Neurosci 25 (2007) 3125-3131
35. Towle M.J., Lee A., Maduakor E.C., Schwartz C.E., Bridges A.J., and Littlefield B.A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53 (1993) 2553-2559
36. Evans D.M., and Sloan-Stakleff K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am Surg 66 (2000) 460-464
37. Todaro L.B., Ladeda V., Bal de Kier Joffe E., and Farias E.F. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Oncol Rep 10 (2003) 725-732
38. de Wit H., and Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 75 (1981) 134-143
39. Shaham Y., Shalev U., Lu L., De Wit H., and Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168 (2003) 3-20
40. Ludwig A.M., and Wikler A. Craving and relapse to drink. Q J Stud Alcohol 35 (1974) 108-130
41. Jaffe J.H., Cascella N.G., Kumor K.M., and Sherer M.A. Cocaine-induced cocaine craving. Psychopharmacology (Berl) 97 (1989) 59-64
42. Brown T.E., Forquer M.R., Cocking D.L., Jansen H.T., Harding J.W., and Sorg B.A. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn Mem 14 (2007) 214-223
43. Sappino A.P., Madani R., Huarte J., Belin D., Kiss J.Z., Wohlwend A., et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 92 (1993) 679-685
44. Salles F.J., and Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 22 (2002) 2125-2134
45. Ma Z., Webb D.J., Jo M., and Gonias S.L. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114 (2001) 3387-3396
46. Vassalli J.D., Sappino A.P., and Belin D. The plasminogen activator/plasmin system. J Clin Invest 88 (1991) 1067-1072
47. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91 (1997) 439-442
48. Fiumelli H., Jabaudon D., Magistretti P.J., and Martin J.L. BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons. Eur J Neurosci 11 (1999) 1639-1646
49. Tsirka S.E., Gualandris A., Amaral D.G., and Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377 (1995) 340-344
50. Tsirka S.E., Rogove A.D., Bugge T.H., Degen J.L., and Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 17 (1997) 543-552
51. Goldfinger L.E., Jiang L., Hopkinson S.B., Stack M.S., and Jones J.C. Spatial regulation and activity modulation of plasmin by high affinity binding to the G domain of the alpha 3 subunit of laminin-5. J Biol Chem 275 (2000) 34887-34893
52. Nakagami Y., Abe K., Nishiyama N., and Matsuki N. Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 20 (2000) 2003-2010
53. Tsirka S.E. Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem Soc Trans 30 (2002) 222-225
54. Fiorillo C.D., Williams J.T., and Bonci A. D1-receptor regulation of synaptic potentials in the ventral tegmental area after chronic drug treatment. Adv Pharmacol 42 (1998) 1002-1005
55. Oray S., Majewska A., and Sur M. Dendritic spine dynamics are regulated by monocular deprivation and extracellular matrix degradation. Neuron 44 (2004) 1021-1030
56. Moonen G., Grau-Wagemans M.P., and Selak I. Plasminogen activator-plasmin system and neuronal migration. Nature 298 (1982) 753-755
57. McGuire P.G., and Seeds N.W. Degradation of underlying extracellular matrix by sensory neurons during neurite outgrowth. Neuron 4 (1990) 633-642
58. Shea T.B., and Beermann M.L. Regulation of neuronal migration and neuritogenesis by distinct surface proteases. Relative contribution of plasmin and a thrombin-like protease. FEBS Lett 307 (1992) 190-194
59. Sumi Y., Dent M.A., Owen D.E., Seeley P.J., and Morris R.J. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development 116 (1992) 625-637
60. Ware J.H., DiBenedetto A.J., and Pittman R.N. Localization of tissue plasminogen activator mRNA in the developing rat cerebellum and effects of inhibiting tissue plasminogen activator on granule cell migration. J Neurobiol 28 (1995) 9-22
61. Frey U., Muller M., and Kuhl D. A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 16 (1996) 2057-2063
62. Baranes D., Lederfein D., Huang Y.Y., Chen M., Bailey C.H., and Kandel E.R. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 21 (1998) 813-825
63. Calabresi P., Napolitano M., Centonze D., Marfia G.A., Gubellini P., Teule M.A., et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 12 (2000) 1002-1012
64. Meiri N., Masos T., Rosenblum K., Miskin R., and Dudai Y. Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning. Proc Natl Acad Sci USA 91 (1994) 3196-3200
65. Madani R., Hulo S., Toni N., Madani H., Steimer T., Muller D., et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18 (1999) 3007-3012
66. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7 (2001) 59-64
67. Nakajima K., Nagata K., and Kohsaka S. Plasminogen mediates an interaction between microglia and dopaminergic neurons. Eur Neurol 34 Suppl 3 (1994) 10-16
68. Robinson T.E., and Berridge K.C. Incentive-sensitization and addiction. Addiction 96 (2001) 103-114
69. Nagai T., Noda Y., Ishikawa K., Miyamoto Y., Yoshimura M., Ito M., et al. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem 92 (2005) 660-667
70. Nagai T., Ito M., Nakamichi N., Mizoguchi H., Kamei H., Fukakusa A., et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 26 (2006) 12374-12383
71. Yan Y., Yamada K., Mizoguchi H., Noda Y., Nagai T., Nitta A., et al. Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice. Neuroscience 146 (2007) 50-59